493PImproving patient selection for immuno-oncology phase I trials: An external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncop ôle (IUCT-O)
ConclusionsThe utilization of theses scores could allow a better patients selection in early trials, especially during the critical periods of dose escalation and proof-of-concept expansion cohorts.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Gastroenterology | Head and Neck Cancer | Legislation | Liver | Melanoma | Skin Cancer | Statistics | Urology & Nephrology